Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Here's the latest Press Release on Novogens anti-cancer drug. It caused a 10% and 19% jump in the share price on the ASX and the NASDAQ respectively.

Lots more good news also contained in a Newsletter to shareholders which Ute kindly reported on over at the Novogen board. Here's the link If you want to join us

http://boards.fool.com/Message.asp?id=1190363000169000&sort=postdate&Posted=1190363000170000&Rep=False

And here's the press release.....

applefoot




06 Jun 2000 08:26
ASX-Novogen LimitedNovogen Anti-Cancer Drug passes First Clinical Hurdle


--------------------------------------------------------------------------------

NOVOGEN LIMITED 2000-06-06 ASX-SIGNAL-G

HOMEX - Sydney

+++++++++++++++++++++++++
Australian pharmaceutical company, Novogen Limited, today announced
the completion of the first stage of Phase 1 clinical evaluation of
its anti-cancer drug, NV-06.

These initial trials were conducted at a major public hospital in
Sydney, Australia, to provide data on blood level changes over time,
and the tolerability of the drug in humans.

NV-06 was delivered as a single intravenous injection to a small
number of cancer patients.

Novogen's Executive Chairman, Dr Graham Kelly, said the initial
results were encouraging.

"NV-06 behaved in the human blood stream just as predicted from
pre-clinical studies," Dr Kelly said.

"The result marked an important milestone in the Company's drug
development program. We have now advanced to the stage where we can
initiate the phase 1b trial involving repeated daily injections in
cancer patients."

Dr Kelly said NV-06 was now in human clinical trials as a treatment
for prostate cancer. The successful treatment of prostate cancer
remains a major challenge in medicine and patients are in need of an
effective well-tolerated therapy.

He added that Novogen considers that NV-06 may also prove effective
against a number of other cancer types.

Novogen has completed a pilot production facility for the manufacture
of NV-06 to approved pharmaceutical standards and will continue to
manufacture the drug throughout the clinical development program.

The Australian Government's research and development START program
has provided funding of up to $2.79 million to assist in the
development of NV-06.

Results of the trial will form part of a submission to the United
States, Food and Drug Administration (FDA), for approval for human
clinical trials to be conducted in cancer patients in the USA.

Novogen is listed on the ASX (code NRT) and in the US on the NASDAQ
(code NVGN).

Issued for: Novogen Limited

For further
information: Mr Christopher Naughton
MANAGING DIRECTOR
Novogen Limited

Dr Graham Kelly
EXECUTIVE CHAIRMAN
Novogen Limited
Tel (02) 9878 0088
http://www.novogen.com






Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.